About Formosa Pharmaceuticals
History
Corporate Development
R&D and Business Development
Aug – Publicly listed on the Taiwan Stock Exchange (TWSE).
Jul - Awarded Innovation of the Year of 2024 by Taiwan BIO Awards.
2024
Aug – Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the treatment of Acute Dry Eye Disease in the U.S. with Eyenovia (More)
Aug – Announced Licensing Agreement with Apotex, for the Commercialization of APP13007 for the Canadian market. (More)
Jul – Announced Licensing Agreement with Tzamal Biomedical, for the Commercialization of APP13007 for the Israeli market.
May – Announced Licensing Agreement with Tabuk, for the Commercialization of APP13007 for the Middle East and North African market. (More)
Mar – Granted FDA Approval for APP13007. (More)
Jan – Announced Licensing Agreement with Cristalia, for the Commercialization of APP13007 for the Brazilian market. (More)
Dec – Received Positive Letter of Opinion from the Taiwan IDA.
2023
Aug – Announced Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the US market. (More)
Jul – Announced FDA Acceptance of NDA Filing for APP13007. (More)
May – Announced the NDA Submission to the US FDA for APP13007. (More)
Feb –Announced Development Collaboration Agreement with Eyenovia. (More)
Jan – Announced a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery. (More)
Aug – Awarded Innovation Award by Taipei Biotech Award Committee
Jul - Awarded Emerging Company of the Year of 2022 by Taiwan BIO Awards.
2022
Nov – conducted successful pre-NDA Meeting with the US FDA and plans for NDA submission of APP13007. (More)
Aug – Announced successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery for APP13007. (More)
May – Announced successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery for APP13007. (More)
